Prospects for submission this year and mid-2020 approval of MorphoSys AG’s first ever proprietary drug were boosted by good Phase II data for MOR208 as a late-stage treatment for refractory diffuse large B-cell lymphoma, analysts and the German group said.
MOR208 (tafasitamab), an Fc-enhanced anti-CD19 monoclonal antibody, in combination with the immunomodulatory drug lenalidomide in r/r DLBCL, met its primary endpoint of best objective response rate (ORR) compared to published data on the respective monotherapies in the ongoing L-MIND Phase II clinical study
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?